Blue Lake Biotechnology

Blue Lake Biotechnology is a private, preclinical-stage biotech focused on next-generation intranasal vaccines. Its core technology is a modified parainfluenza virus 5 (PIV5) vector, engineered to express target antigens, which is delivered as a nasal spray to induce robust mucosal, cellular, and humoral immunity. The platform leverages PIV5's long safety record in animals, potential for single-dose efficacy, and scalable manufacturing to target infectious diseases, with an initial focus on respiratory pathogens. The company is positioned to address key limitations of injectable vaccines, including transmission blocking and broad global deployment.

Proprietary intranasal vaccine platform based on a modified parainfluenza virus 5 (PIV5) vector, engineered to express target antigens. Designed to induce mucosal, cellular, and humoral immunity through self-limited replication in the respiratory tract.

Competes with other companies developing intranasal/mucosal vaccines (e.g., Codagenix, Meissa Vaccines, Altimmune) and established injectable vaccine giants (GSK, Pfizer, Sanofi). Differentiation hinges on PIV5's safety profile, potential for single-dose efficacy, and manufacturing advantages.